Similar articles for PMID: 25240816

Year	Number of Results
2002	2
2003	2
2004	1
2005	4
2006	3
2007	4
2008	7
2009	5
2010	3
2011	6
2012	9
2013	13
2014	15
2015	12
2016	15
2017	9
2018	10
2019	10
2020	24
2021	27
2022	52
2023	26
2024	0

1

Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.

Grunwald MR, Tseng LH, Lin MT, Pratz KW, Eshleman JR, Levis MJ, Gocke CD. Grunwald MR, et al. Biol Blood Marrow Transplant. 2014 Dec;20(12):1989-95. doi: 10.1016/j.bbmt.2014.08.015. Epub 2014 Aug 23. Biol Blood Marrow Transplant. 2014. PMID: 25240816 Free PMC article.

2

Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation.

Helbig G, Koclęga A, Wieczorkiewicz-Kabut A, Woźniczka K, Kopińska A, Boral K, Grygoruk-Wiśniowska I, Stachowicz M, Karolczyk A. Helbig G, et al. Ann Hematol. 2020 Aug;99(8):1845-1853. doi: 10.1007/s00277-020-04026-1. Epub 2020 Apr 24. Ann Hematol. 2020. PMID: 32333156 Free PMC article. Clinical Trial.

3

A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML.

Lin MT, Tseng LH, Dudley JC, Riel S, Tsai H, Zheng G, Pratz KW, Levis MJ, Gocke CD. Lin MT, et al. Mol Diagn Ther. 2015 Dec;19(6):409-17. doi: 10.1007/s40291-015-0170-3. Mol Diagn Ther. 2015. PMID: 26446915 Free PMC article.

4

The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.

Zheng WS, Hu YL, Guan LX, Peng B, Wang SY. Zheng WS, et al. Hematology. 2021 Dec;26(1):179-185. doi: 10.1080/16078454.2021.1880753. Hematology. 2021. PMID: 33594943

5

Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.

Fleischmann M, Schnetzke U, Schrenk KG, Schmidt V, Sayer HG, Hilgendorf I, Hochhaus A, Scholl S. Fleischmann M, et al. J Cancer Res Clin Oncol. 2017 Feb;143(2):337-345. doi: 10.1007/s00432-016-2290-5. Epub 2016 Oct 24. J Cancer Res Clin Oncol. 2017. PMID: 27778197

6

Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia.

Schiller J, Praulich I, Krings Rocha C, Kreuzer KA. Schiller J, et al. Eur J Haematol. 2012 Jul;89(1):53-62. doi: 10.1111/j.1600-0609.2012.01785.x. Epub 2012 May 9. Eur J Haematol. 2012. PMID: 22458420

7

Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.

Al Hamed R, Labopin M, Daguindau E, Niittyvuopio R, Huynh A, Socié G, Srour M, Henri Bourhis J, Kröger N, Tholouli E, Choi G, Poiré X, Martin H, Rubio MT, Jindra P, Blaise D, Beelen D, Labussière-Wallet H, Nagler A, Bazarbachi A, Mohty M. Al Hamed R, et al. Cancer Med. 2022 Feb;11(4):1068-1080. doi: 10.1002/cam4.4218. Epub 2022 Jan 20. Cancer Med. 2022. PMID: 35048553 Free PMC article.

8

Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.

Wang J, Dao FT, Wang Y, Jiang H, Xu LP, Zhao XS, Zhang XH, Liu KY, Huang XJ, Jiang Q, Qin YZ. Wang J, et al. Hematol Oncol. 2022 Oct;40(4):724-733. doi: 10.1002/hon.3015. Epub 2022 May 15. Hematol Oncol. 2022. PMID: 35531760

9

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).

Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C, Wollmer E, Wäsch R, Bornhäuser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner EM, Kröger N, Wolschke C, Schleuning M, Götze KS, Schmid C, Crysandt M, Eßeling E, Wolf D, Wang Y, Böhm A, Thiede C, Haferlach T, Michel C, Bethge W, Wündisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes HG, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder SK. Burchert A, et al. J Clin Oncol. 2020 Sep 10;38(26):2993-3002. doi: 10.1200/JCO.19.03345. Epub 2020 Jul 16. J Clin Oncol. 2020. PMID: 32673171 Clinical Trial.

10

Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.

Wang H, Li XQ, Chu TT, Han SY, Qi JQ, Tang YQ, Qiu HY, Fu CC, Tang XW, Ruan CG, Wu DP, Han Y. Wang H, et al. J Cancer Res Clin Oncol. 2021 Sep;147(9):2659-2670. doi: 10.1007/s00432-021-03530-9. Epub 2021 Feb 7. J Cancer Res Clin Oncol. 2021. PMID: 33550446

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

218 results

Results by year